2025
Defining a lineage-specific chimerism threshold for the use of donor lymphocyte infusions in treating myeloid malignancies
Puzo C, Seropian S, Rinder H, Tormey C, Siddon A. Defining a lineage-specific chimerism threshold for the use of donor lymphocyte infusions in treating myeloid malignancies. Bone Marrow Transplantation 2025, 1-3. PMID: 39806028, DOI: 10.1038/s41409-025-02510-8.Peer-Reviewed Original Research
2024
Optimization criteria for ordering myeloid neoplasm next‐generation sequencing
Gisriel S, Howe J, Tormey C, Torres R, Hager K, Rinder H, Siddon A. Optimization criteria for ordering myeloid neoplasm next‐generation sequencing. EJHaem 2024, 5: 1236-1242. PMID: 39691272, PMCID: PMC11647727, DOI: 10.1002/jha2.1036.Peer-Reviewed Original ResearchNext-generation sequencingNext-generation sequencing testMyeloid neoplasmsDiagnosis of chronic myeloid leukemiaAltering treatment plansEnd-of-inductionFluorescence in situ hybridizationRecurrence post-transplantChronic myeloid leukemiaSuspicion of progressionPathogenic mutationsClinical suspicionMutation statusMN diagnosisMyeloid leukemiaPost-transplantRisk stratificationWorsening diseaseTreatment planningCancellation criteriaSuspicionDiagnosisSequenceCenters for MedicareB testThe effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges
Puzo C, Li P, Tormey C, Siddon A. The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges. Lab Medicine 2024, 56: 187-194. PMID: 39303673, DOI: 10.1093/labmed/lmae080.Peer-Reviewed Original ResearchAutologous stem cell transplantationHematopoietic stem cellsMultiple myelomaG-CSFMobilization failureDiffuse large B-cell lymphomaAutologous stem cell mobilizationLarge B-cell lymphomaGranulocyte colony-stimulating factorAutologous stem cell transplant patientsEfficacy of plerixaforStem cell mobilizationB-cell lymphomaStem cell transplantationEffects of plerixaforRetrospective chart reviewColony-stimulating factorYale-New Haven HospitalCell viabilityMultiple risk factorsHodgkin lymphomaNon-HodgkinMobilization regimenCell transplantationPlerixaforMixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation
Yurtsever N, Lee E, Pinatti L, Shah B, Tormey C, Siddon A. Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation. Immunohematology 2024, 40: 89-92. PMID: 39373301, PMCID: PMC11700658, DOI: 10.2478/immunohematology-2024-013.Peer-Reviewed Original ResearchConceptsStem cell transplantationCell transplantationDisease recurrenceMyeloid neoplasmsChimerism testingAllogeneic stem cell transplantationSigns of disease recurrenceIndicator of disease recurrenceDonor-recipient pairsABO antigen expressionGraft statusAntigen expressionFemale patientsPost-transplantationAllograft statusTransplantationABO typeRecurrenceClinical settingEarly signsNeoplasmsChimerismEarly indicatorABOEngraftment
2021
Development of anti-Jk3 associated with silenced Kidd antigen expression and a novel single nucleotide variant of the JK gene
Manrai PA, Siddon AJ, Hager KM, Hendrickson JE, Keller MA, Tormey CA. Development of anti-Jk3 associated with silenced Kidd antigen expression and a novel single nucleotide variant of the JK gene. Immunohematology 2021, 37: 109-112. PMID: 34591379, DOI: 10.21307/immunohematology-2021-015.Peer-Reviewed Original ResearchConceptsHigh-prevalence antigenReagent red blood cellsDirect antiglobulin testBlood samplesBlood group APatient blood samplesImmunohematology reference laboratoryRare alloantibodyRed blood cellsOncologic careAntiglobulin testGroup APolynesian descentBlood cellsNon-conservative amino acid changeSingle nucleotide variantsReference laboratoryAmino acid changesFamilial backgroundExon 8Antigen expressionExon 7Nucleotide variantsAcid changesExon 4Behind the scenes with basophils: an emerging therapeutic target
Shah H, Eisenbarth S, Tormey CA, Siddon AJ. Behind the scenes with basophils: an emerging therapeutic target. Immunotherapy Advances 2021, 1: ltab008. PMID: 35919744, PMCID: PMC9327101, DOI: 10.1093/immadv/ltab008.Peer-Reviewed Original ResearchChronic myeloid leukemiaImmunoregulatory functionsMyeloproliferative neoplasmsType 2 cytokinesCD4 T cell differentiationDevelopment of immunotherapyNon-malignant diseasesT cell differentiationB cell activationBasophil biologyMalignant disease statesAllergic inflammationInflammatory mediatorsBasophil degranulationPeripheral bloodAllergic responsesIL-4Th2 cellsAberrant immunophenotypeMyeloid leukemiaAdaptive immunityHematological malignanciesMast cellsMyeloid neoplasmsDiagnostic criteria
2020
Assessment of Factor V Activity in Apheresis Platelet Units: Implications for Management of FV Deficiency
Gupta G, Hendrickson J, Bahel P, Siddon A, Rinder H, Tormey C. Assessment of Factor V Activity in Apheresis Platelet Units: Implications for Management of FV Deficiency. American Journal Of Clinical Pathology 2020, 154: s6-s7. DOI: 10.1093/ajcp/aqaa137.011.Peer-Reviewed Original ResearchImpact of intra-tumoral heterogeneity detected by next-generation sequencing on acute myeloid leukemia survival
Schulz WL, Rinder HM, Durant TJS, Tormey CA, Torres R, Smith BR, Hager KM, Howe JG, Siddon AJ. Impact of intra-tumoral heterogeneity detected by next-generation sequencing on acute myeloid leukemia survival. Leukemia & Lymphoma 2020, 61: 3269-3271. PMID: 32715805, DOI: 10.1080/10428194.2020.1797016.Peer-Reviewed Original ResearchCharacterization of circulating and cultured Tfh-like cells in sickle cell disease in relation to red blood cell alloimmunization status
Balbuena-Merle R, Santhanakrishnan M, Devine L, Gibb DR, Tormey CA, Siddon AJ, Curtis SA, Gallagher PG, Weinstein JS, Hendrickson JE. Characterization of circulating and cultured Tfh-like cells in sickle cell disease in relation to red blood cell alloimmunization status. Transfusion And Apheresis Science 2020, 59: 102778. PMID: 32439490, PMCID: PMC7483805, DOI: 10.1016/j.transci.2020.102778.Peer-Reviewed Original ResearchConceptsTfh-like cellsNaïve CD4 T cellsSickle cell diseaseCD4 T cellsCD4 T cell subsetsT cell subsetsT cellsCell diseaseRed blood cell alloimmunizationPeripheral blood mononuclear cellsBlood mononuclear cellsCD3/CD28Electronic medical recordsAlloimmunization statusHLA alloantibodiesRBC autoantibodiesRBC alloantibodiesFollicular helperIL-12Mononuclear cellsMedical recordsIL-7Antigen specificityB cellsAlloantibodiesThe Development and Implementation of a Novel Electronic Consult System by a Laboratory Medicine Service: Experience From the First 2 Years of Use
Stendahl K, Siddon AJ, Peaper DR, Hauser RG, Campbell S, Tormey CA. The Development and Implementation of a Novel Electronic Consult System by a Laboratory Medicine Service: Experience From the First 2 Years of Use. Archives Of Pathology & Laboratory Medicine 2020, 145: 75-81. PMID: 33367659, DOI: 10.5858/arpa.2019-0267-oa.Peer-Reviewed Original ResearchConceptsE-consultsMedicine serviceLaboratory medicine servicesConsult systemPeripheral blood smear reviewE-consult implementationMajority of consultsType of consultBlood smear reviewHematology/oncologyMedian turnaround timeHealth care facilitiesPrimary careMedical recordsProvider communicationClinical impactResident reviewCare facilitiesSmear reviewTest utilizationPathologist reviewYears of useBlood bankConsultsUtilization trendsInvestigation of increased platelet alloimmunization screening in the era of pathogen‐reduced platelets treated with psoralen/UV light
Hendrickson JE, Mendoza H, Ross R, Siddon AJ, Gowda L, Hauser RG, Schulz WL, Tormey CA. Investigation of increased platelet alloimmunization screening in the era of pathogen‐reduced platelets treated with psoralen/UV light. Transfusion 2020, 60: 650-651. PMID: 32128834, DOI: 10.1111/trf.15691.Peer-Reviewed Original Research
2019
Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease
Balbuena‐Merle R, Curtis SA, Devine L, Gibb DR, Karafin MS, Luckey CJ, Tormey CA, Siddon AJ, Roberts JD, Hendrickson JE. Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease. Transfusion 2019, 59: 3219-3227. PMID: 31355970, PMCID: PMC7075520, DOI: 10.1111/trf.15463.Peer-Reviewed Original ResearchConceptsSickle cell diseaseMonocyte subsetsTotal monocytesCell diseaseComplications of SCDRed blood cell alloimmunizationRed blood cell alloantibodiesElectronic medical recordsTransfusion exposureSerum cytokinesIntermediate monocytesRBC alloantibodiesInflammatory milieuCD64 expressionClassical monocytesPeripheral bloodInflammatory functionsMedical recordsAntibody formationClinical significancePatientsMonocytesFlow cytometryLow expressionResponders
2018
Modified approach to fibrinogen replacement in the setting of dysfibrinogenaemia
Chandler JB, Siddon AJ, Bahel P, Torres R, Rinder HM, Tormey CA. Modified approach to fibrinogen replacement in the setting of dysfibrinogenaemia. Journal Of Clinical Pathology 2018, 72: 177-180. PMID: 30463936, DOI: 10.1136/jclinpath-2018-205438.Peer-Reviewed Original ResearchDelayed haemolytic and serologic transfusion reactions
Siddon AJ, Kenney BC, Hendrickson JE, Tormey CA. Delayed haemolytic and serologic transfusion reactions. Current Opinion In Hematology 2018, 25: 459-467. PMID: 30124474, DOI: 10.1097/moh.0000000000000462.Peer-Reviewed Original ResearchConceptsSickle cell diseaseAdverse eventsTransfusion reactionsTransfusion-associated adverse eventsHaemolytic transfusion reactionsSerologic transfusion reactionsGeneral patient groupNovel immunosuppressive agentPractical preventive strategiesEvidence-based approachImmune dysregulationImmunosuppressive agentsPatient groupTransfusion recipientsRisk factorsBasic epidemiologyCell diseasePreventive strategiesRed blood cell deathAntibody detectionDHTRHaemolytic reactionsMultitude of reportsCell deathDHTRsFalse-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab
Chen PP, Tormey CA, Eisenbarth SC, Torres R, Richardson SS, Rinder HM, Smith BR, Siddon AJ. False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab. American Journal Of Clinical Pathology 2018, 151: 154-163. PMID: 30307483, DOI: 10.1093/ajcp/aqy129.Peer-Reviewed Original ResearchConceptsHealthy donor bloodAlemtuzumab treatmentDonor bloodBone marrowFlow cytometryLight chain restrictionT-cell prolymphocytic leukemiaB-cell neoplasmsLight chain clonalityFlow cytometry analysisAutoimmune diseasesHematologic malignanciesImmunophenotypic analysisChain restrictionAlemtuzumabT cellsB cellsProlymphocytic leukemiaImmunoglobulin G1PatientsMonoclonal antibodiesCytometry analysisSimilar findingsBloodClonal restrictionVisualization of bacterial contamination in an apheresis platelet unit
Siddon AJ, Snyder EL, Tormey CA. Visualization of bacterial contamination in an apheresis platelet unit. Journal Of Clinical Apheresis 2018, 33: 671-672. PMID: 30242893, DOI: 10.1002/jca.21649.Peer-Reviewed Original ResearchMorphology and flow cytometry of atypical basophils
Tormey CA, Siddon AJ. Morphology and flow cytometry of atypical basophils. Blood 2018, 132: 552. PMID: 30072417, DOI: 10.1182/blood-2018-05-850073.Peer-Reviewed Original Research
2017
R634W KIT Mutation in an Adult With Systemic Mastocytosis
Astle JM, Rose MG, Racke FK, Tormey CA, Siddon AJ. R634W KIT Mutation in an Adult With Systemic Mastocytosis. Lab Medicine 2017, 48: 253-257. PMID: 28520972, DOI: 10.1093/labmed/lmx026.Peer-Reviewed Original Research
2016
Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice
Liu J, Santhanakrishnan M, Natarajan P, Gibb DR, Eisenbarth SC, Tormey CA, Siddon AJ, Stowell SR, Branch DR, Hendrickson JE. Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice. Blood 2016, 128: 3159-3168. PMID: 27688803, PMCID: PMC5201095, DOI: 10.1182/blood-2016-06-724732.Peer-Reviewed Original ResearchConceptsMechanism of actionKO miceRed blood cell alloimmunizationGlycoprotein antigenMurine RBCsHuman KEL glycoproteinRh immune globulinSingle knockout miceWild-type recipientsImmunoprophylaxis programKO recipientsPrevent alloimmunizationImmune globulinSerious complicationsAntigen modulationMurine modelImmunoprophylaxisFcγ receptorsKEL antigenAlloimmunizationFlow cytometryRapid clearanceWestern blotMiceAntigenSuccessful Use of Four Factor-Prothrombin Complex Concentrate for Congenital Factor X Deficiency in the Setting of Neurosurgery
Siddon AJ, Tormey CA. Successful Use of Four Factor-Prothrombin Complex Concentrate for Congenital Factor X Deficiency in the Setting of Neurosurgery. Lab Medicine 2016, 47: e35-e37. PMID: 27378481, PMCID: PMC4985779, DOI: 10.1093/labmed/lmw037.Peer-Reviewed Original ResearchConceptsCongenital factor X deficiencyFactor X deficiencyX deficiencyExcessive bleedingComplex concentrateFour-factor prothrombin complex concentrateFactor prothrombin complex concentrateFirst-line therapyAnterior cervical discectomySetting of traumaProthrombin complex concentrateFresh frozen plasmaRare coagulation disorderMajor neurosurgeryCervical discectomyThromboembolic complicationsSpontaneous hemorrhageCoagulation disordersFrozen plasmaInvasive proceduresOperative casesBleedingWhite menDeficiencyDisorders
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply